- Home
- Equipment
- asia middle east
- t and b cell
Show results for
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Eutilex T And B Cell Equipment Supplied In Asia Middle East
4 equipment items found
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
Fully humanized therapeutic monoclonal antibody. This could convert type II macrophage to Type I. Anti-tumor efficacy of the antibody can be achieved by modulating tumor ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy. The epitopes recognized by HLA-DR are not shed or internalized, enabling stable binding to human lymphoma cells. MVR CAR-T can also be used in patients who relapse after CD19 CAR-T treatment. Reduction of cytokine ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T; Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo; Clear anti-cancer efficacy in an orthotopic model; Smaller number of 4th generation GPC3 CAR-T required than other groups to remove ...